Hereditary Transthyretin Amyloidosis: How to Differentiate Carriers and Patients Using Speckle-Tracking

Daniela Di Lisi1,2, Filippo Brighina3, Girolamo Manno1,2

  • 1Division of Cardiology, University Hospital Paolo Giaccone, 90127 Palermo, Italy.

PubMed

Insights

Early detection of cardiac involvement in hereditary transthyretin amyloidosis is possible. The apical/basal longitudinal strain ratio (SAB) and relative apical sparing (RAS) can help differentiate carriers from patients with TTR gene mutations.

Area of Science:

  • Cardiology
  • Genetics
  • Neurology

Background:

  • Hereditary transthyretin amyloidosis results from transthyretin (TTR) gene mutations.
  • Early identification of cardiac involvement is crucial for differentiating carriers from patients with TTR-related diseases.

Purpose of the Study:

  • To identify early indicators of cardiac involvement in TTR mutation carriers.
  • To distinguish between carriers, patients with polyneuropathy, and those with both cardiac amyloidosis and polyneuropathy.

Main Methods:

  • A case-control study involving 31 subjects with TTR mutations.
  • Patients categorized into three groups: cardiac amyloidosis/polyneuropathy, polyneuropathy only, and carriers.
  • Speckle-tracking echocardiography assessed left-ventricular global longitudinal strain (GLS), atrial stiffness, apical/basal longitudinal strain ratio (SAB), and relative apical sparing (RAS).

Main Results:

  • Significant differences in SAB and RAS were observed between carriers (Group C) and patients with polyneuropathy (Group B).
  • SAB and RAS were more impaired in patients with cardiac amyloidosis and polyneuropathy (Group A) compared to those with only polyneuropathy (Group B).
  • Atrial stiffness was significantly impaired in both Group A and Group B compared to Group C.

Conclusions:

  • The apical/basal longitudinal strain ratio (SAB) and relative apical sparing (RAS) show diagnostic potential for cardiac amyloidosis.
  • SAB and RAS demonstrate a progressive decline from carriers to patients with neurological and cardiac involvement.
  • SAB, RAS, and atrial stiffness may serve as monitoring tools for TTR mutation carriers, warranting further investigation.
Abstract